ACS chemical neuroscience molecule spotlight on ELND006: Another γ-secretase inhibitor fails in the clinic

Corey R. Hopkins

doi:10.1021/cn2000469

ACS chemical neuroscience molecule spotlight on ELND006: Another γ-secretase inhibitor fails in the clinic

Corey R. Hopkins

Research output: Contribution to journal › Review article

33 Scopus citations

Abstract

ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule γ-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroom.lilly.com/releasedetail.cfm? releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.

Original language	English (US)
Pages (from-to)	279-280
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	2
Issue number	6
DOIs	https://doi.org/10.1021/cn2000469
State	Published - Jun 15 2011

Keywords

Alzheimer's disease
ELND006
clinical trials
semagacestat
γ-secretase

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn2000469

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on ELND006: Another γ-secretase inhibitor fails in the clinic'. Together they form a unique fingerprint.

Cite this

Hopkins, C. R. (2011). ACS chemical neuroscience molecule spotlight on ELND006: Another γ-secretase inhibitor fails in the clinic. ACS Chemical Neuroscience, 2(6), 279-280. https://doi.org/10.1021/cn2000469

@article{99e177e147074d3aa177ad17ac293523,

title = "ACS chemical neuroscience molecule spotlight on ELND006: Another γ-secretase inhibitor fails in the clinic",

abstract = "ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule γ-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroom.lilly.com/releasedetail.cfm? releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.",

keywords = "Alzheimer's disease, ELND006, clinical trials, semagacestat, γ-secretase",

author = "Hopkins, {Corey R.}",

year = "2011",

month = jun,

day = "15",

doi = "10.1021/cn2000469",

language = "English (US)",

volume = "2",

pages = "279--280",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "6",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on ELND006

T2 - Another γ-secretase inhibitor fails in the clinic

AU - Hopkins, Corey R.

PY - 2011/6/15

Y1 - 2011/6/15

N2 - ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule γ-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroom.lilly.com/releasedetail.cfm? releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.

AB - ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule γ-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroom.lilly.com/releasedetail.cfm? releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.

KW - Alzheimer's disease

KW - ELND006

KW - clinical trials

KW - semagacestat

KW - γ-secretase

UR - http://www.scopus.com/inward/record.url?scp=79959223299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959223299&partnerID=8YFLogxK

U2 - 10.1021/cn2000469

DO - 10.1021/cn2000469

M3 - Review article

C2 - 22778871

AN - SCOPUS:79959223299

VL - 2

SP - 279

EP - 280

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 6

ER -